Cas Lamvac (Guangzhou) Biomedical Technology Co., Ltd.

Bluelight Pharmatech Co., Ltd.

Guangzhou Cas Lamvac Biotech Co., Ltd

Cas Lamvac Biomedical Technology Co., Ltd.

Li Qin

Xiaoping Chen

Hongxing Wang

Yinzhou Fan

Shuanghong Liang

Ting Jiang

Wen Hu

Xiaoyi Huang

Yongchao Yao

Zhu Tao

Wenzhong Guo

Huihui Zhang

Jiaojiao Li

Shuozhou Huang

Yinbo Jiang

Yanli Gu

Zhenping Huang

Siting Zhao

Ying Tong

Meiling Wang

Jianhua Su

Xingxiang Liang

Provided are a chimeric antigen receptor and an application thereof; said chimeric antigen receptor contains a domain which identifies any one of, or a combination of at least two of, the malarial protein VAR2CSA, a protein tag on malarial protein VAR2CSA, or a compound capable of labeling the malarial protein VAR2CSA. The chimeric antigen receptor can identify the VAR2CSA protein or the recombinant protein (rVAR2) of any one of, or at least two of, the domains of the VAR2CSA protein which can bind to placental-like chondroitin sulfate A (pl-CSA). The VAR2CSA protein or rVAS2 protein is capable of targeting several different types of tumor cells by means of binding to the pl-CSA on the surface of the tumor cell.

Chimeric antigen receptor and application thereof

Hot-melt extrusion for producing solid solution comprising nanoparticle formulation of decoquinate is disclosed. Aqueous phase comprising the nanoparticles of hot-melt extruding products is homogeneous and stable. Provided is the composition comprising the solid solution of decoquinate and a method of hot-melt extrusion for producing this composition comprising the solid dispersion of decoquinate. Furthermore, provided is the solid solution comprising nanosized decoquinate formulation having improved water solubility and enhanced delivery of decoquinate in digestive system for absorption, increasing bioavailability, and the efficacy against malaria at the liver stage.

Nanoparticle formulations of decoquinate in the form of solid solution

Disclosed are an attenuation system and the use thereof for attenuating plasmodia, specifically the use of an EF1g gene for attenuating plasmodia. The attenuation system regulates the expression or degradation of the EF1g gene by using a regulatory system, thereby controlling the growth of plasmodia and achieving the attenuation of plasmodia.

Attenuation system and use thereof

Implants comprising an antimalarial agent such as decoquinate or another therapeutic drug are disclosed. The implants can be in the form of a complex comprising a drug, a lipid or lipids and optionally a polymer carrier. The present invention provides methods for preparing implants wherein the implants comprise decoquinate or another therapeutic drug, and a lipid or lipids such as cholesterol, monoglycerides, or diglycerides, and optionally a small percentage of a biocompatible polymer based on the total implant weight. The implants are useful for releasing a therapeutic drug at a constant level and maintaining a prophylactic or therapeutic level of the drug in a subject, for preventing a malarial infection or treating other diseases or disorders.

Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof

Growing community of inventors

Guangzhou, China

Li Qin